FDA OKs Sangamo’s IND for gene therapy candidate for hemophilia A; shares ahead 7% premarket – Seeking Alpha
Community Financial News |
FDA OKs Sangamo’s IND for gene therapy candidate for hemophilia A; shares ahead 7% premarket
Seeking Alpha The FDA clears Sangamo BioSciences’ (NASDAQ:SGMO) Investigational New Drug (IND) application for gene therapy candidate SB-525 for the treatment of hemophilia A. Phase 1 development to assess safety, tolerability and potential efficacy may now … Sangamo BioSciences Announces FDA Clearance Of Investigational New Drug Application For SB-525 Gene Therapy …PR Newswire (press release) |
Community Financial News |
FDA OKs Sangamo’s IND for gene therapy candidate for hemophilia A; shares ahead 7% premarket
Seeking Alpha The FDA clears Sangamo BioSciences’ (NASDAQ:SGMO) Investigational New Drug (IND) application for gene therapy candidate SB-525 for the treatment of hemophilia A. Phase 1 development to assess safety, tolerability and potential efficacy may now … Sangamo BioSciences Announces FDA Clearance Of Investigational New Drug Application For SB-525 Gene Therapy …PR Newswire (press release) |
Community Financial News |
FDA OKs Sangamo’s IND for gene therapy candidate for hemophilia A; shares ahead 7% premarket
Seeking Alpha The FDA clears Sangamo BioSciences’ (NASDAQ:SGMO) Investigational New Drug (IND) application for gene therapy candidate SB-525 for the treatment of hemophilia A. Phase 1 development to assess safety, tolerability and potential efficacy may now … Sangamo BioSciences Announces FDA Clearance Of Investigational New Drug Application For SB-525 Gene Therapy …PR Newswire (press release) |
|
Janssen Enters Immunotherapy Clinical Collaboration with Bristol-Myers Squibb to Evaluate daratumumab …
PR Newswire (press release) “Immunotherapy has vastly changed the way cancer is treated. We are excited to study this novel combination of two potentially synergistic immunotherapies,” said Peter F. Lebowitz, M.D., Ph.D., Global Oncology Head, Janssen Research & Development, LLC … |
|
Bristol-Myers Squibb Announces Immunotherapy Clinical Collaboration with Janssen to Evaluate Opdivo (nivolumab …
Business Wire (press release) This agreement builds off Bristol-Myers Squibb and Janssen’s previous clinical research collaboration announced in July, 2016 to evaluate Opdivo and Janssen’s Live Attenuated Double–Deleted (LADD) Listerial monocytogenes cancer immunotherapy, … |
|
Immunotherapy team harnesses cellular systems to fight diseases
Medical Xpress Mario Otto, MD, PhD, (right) leads research on processes used in immunotherapy in his lab. Credit: University of Wisconsin-Madison. Four decades ago, researchers at the University of Wisconsin School of Medicine and Public Health had the right idea—to … |